📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Neurelis

1.1 - Company Overview

Neurelis Logo

Neurelis

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of specialty pharmaceutical therapies addressing unmet medical needs, including VALTOCO, a prescription nasal spray for short-term treatment of seizure clusters in patients aged 6 and older; and pipeline programs NRL-1004 for acute agitation using proprietary Intravail delivery technology, and NRL-1049 for cerebral cavernous malformations, potentially the first FDA-approved treatment.

Products and services

  • VALTOCO: Delivers prescription-grade nasal spray for short-term treatment of seizure clusters in patients aged 6 years and older via intranasal administration
  • NRL-1049: First-in-class new chemical entity in development to treat cerebral cavernous malformations, potentially becoming the first FDA-approved therapy for this condition
  • NRL-1004: Proprietary, Intravail-enabled candidate under development for acute agitation, utilizing Intravail drug delivery technology for acute agitation treatment

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Neurelis

Baergic Bio Logo

Baergic Bio

HQ: United States Website
  • Description: Provider of novel therapeutics for the treatment of central nervous system (CNS) disorders, developed and commercialised by a biopharmaceutical company.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Baergic Bio company profile →
Bonti Logo

Bonti

HQ: United States Website
  • Description: Provider of biotechnology, based in Orange, California. Founded in 2015 by Fauad Hasan, Mike Jarpe, Susan Abushakra, and Wajdie Ahmad.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Bonti company profile →
Lundbeck Logo

Lundbeck

HQ: Denmark Website
  • Description: Provider of pharmaceuticals for psychiatric and neurological disorders, engaged globally in the research, development, production, marketing, and sale of these products.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Lundbeck company profile →
iZumi Bio Logo

iZumi Bio

HQ: United States Website
  • Description: Provider of biotechnology solutions leveraging cellular reprogramming, including induced pluripotent stem cells and directed differentiation, to develop stem cell-based therapeutics.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full iZumi Bio company profile →
Trevena Logo

Trevena

HQ: United States Website
  • Description: Provider of an approved intravenous opioid analgesic (OLINVYK) for the management of acute pain in adults when alternative treatments are inadequate, and developer of GPCR-biased ligands, including TRV045 (oral S1P receptor; diabetic neuropathic pain and epilepsy; Phase 1), TRV250 (delta receptor; acute migraine; Phase 1), and TRV734 (oral mu receptor; maintenance treatment of opioid use disorder; Phase 1).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Trevena company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Neurelis

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Neurelis

2.2 - Growth funds investing in similar companies to Neurelis

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Neurelis

4.2 - Public trading comparable groups for Neurelis

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Neurelis

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Neurelis

What does Neurelis do?

Neurelis is a provider of specialty pharmaceutical therapies addressing unmet medical needs, including VALTOCO, a prescription nasal spray for short-term treatment of seizure clusters in patients aged 6 and older; and pipeline programs NRL-1004 for acute agitation using proprietary Intravail delivery technology, and NRL-1049 for cerebral cavernous malformations, potentially the first FDA-approved treatment.

Who are Neurelis's competitors?

Neurelis's competitors and similar companies include Baergic Bio, Bonti, Lundbeck, iZumi Bio, and Trevena.

Where is Neurelis headquartered?

Neurelis is headquartered in United States.

How many employees does Neurelis have?

Neurelis has 1,000 employees 🔒.

When was Neurelis founded?

Neurelis was founded in 2010 🔒.

What sector and industry vertical is Neurelis in?

Neurelis is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Neurelis

Who are the top strategic acquirers in Neurelis's sector and industry

Top strategic M&A buyers and acquirers in Neurelis's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Neurelis?

Top strategic M&A buyers groups and sectors for Neurelis include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Neurelis's sector and industry vertical

Which are the top PE firms investing in Neurelis's sector and industry vertical?

Top PE firms investing in Neurelis's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Neurelis's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Neurelis's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Neurelis's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Neurelis include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Neurelis's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Neurelis?

The key public trading comparables and valuation benchmarks for Neurelis include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Neurelis for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Neurelis with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Neurelis's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Neurelis with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Neurelis's' sector and industry vertical?

Access recent funding rounds and capital raises in Neurelis's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Neurelis